DE69203424T2 - N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)Propylamine als Norepinephrineinhibitoren. - Google Patents

N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)Propylamine als Norepinephrineinhibitoren.

Info

Publication number
DE69203424T2
DE69203424T2 DE69203424T DE69203424T DE69203424T2 DE 69203424 T2 DE69203424 T2 DE 69203424T2 DE 69203424 T DE69203424 T DE 69203424T DE 69203424 T DE69203424 T DE 69203424T DE 69203424 T2 DE69203424 T2 DE 69203424T2
Authority
DE
Germany
Prior art keywords
compound
pharmaceutically acceptable
phenyl
norepinephrine
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69203424T
Other languages
German (de)
English (en)
Other versions
DE69203424D1 (de
Inventor
Donald Richard Gehlert
David Wayne Robertson
David Taiwai Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69203424D1 publication Critical patent/DE69203424D1/de
Publication of DE69203424T2 publication Critical patent/DE69203424T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/29—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69203424T 1991-09-27 1992-09-24 N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)Propylamine als Norepinephrineinhibitoren. Expired - Fee Related DE69203424T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/766,993 US5281624A (en) 1991-09-27 1991-09-27 N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
DE69203424D1 DE69203424D1 (de) 1995-08-17
DE69203424T2 true DE69203424T2 (de) 1996-01-11

Family

ID=25078150

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69203424T Expired - Fee Related DE69203424T2 (de) 1991-09-27 1992-09-24 N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)Propylamine als Norepinephrineinhibitoren.

Country Status (23)

Country Link
US (1) US5281624A (enExample)
EP (1) EP0534756A3 (enExample)
JP (2) JPH05238996A (enExample)
KR (1) KR100221180B1 (enExample)
CN (1) CN1033580C (enExample)
AT (1) ATE124934T1 (enExample)
AU (1) AU655075B2 (enExample)
BR (2) BR9203743A (enExample)
CA (2) CA2079161C (enExample)
CZ (1) CZ281817B6 (enExample)
DE (1) DE69203424T2 (enExample)
FI (1) FI111250B (enExample)
HU (1) HU215519B (enExample)
IL (1) IL103277A (enExample)
MX (1) MX9205433A (enExample)
MY (1) MY108304A (enExample)
NO (1) NO178109C (enExample)
NZ (1) NZ244460A (enExample)
RU (1) RU2057120C1 (enExample)
SK (1) SK290892A3 (enExample)
TW (1) TW249225B (enExample)
YU (1) YU87192A (enExample)
ZA (1) ZA927240B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
AU709704B2 (en) * 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
CN1301164A (zh) * 1998-04-09 2001-06-27 法玛西雅厄普约翰美国公司 神经病症的新疗法
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
ES2305606T3 (es) 1999-04-06 2008-11-01 Sepracor Inc. Succinato de o-desmetilvenlafaxina.
IL146564A0 (en) 1999-05-24 2002-07-25 Mitsubishi Pharma Corp Phenoxypropylamine derivatives and pharmaceutical compositions containing the same
JP2003503450A (ja) * 1999-07-01 2003-01-28 ファルマシア・アンド・アップジョン・カンパニー 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
AU2002347984A1 (en) * 2001-11-30 2003-06-17 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
DE60223718T2 (de) * 2001-12-11 2008-10-30 Eli Lilly And Co., Indianapolis Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
AU2004227945B2 (en) * 2003-04-04 2006-10-26 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
EP1660065A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
ITMI20061987A1 (it) * 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
WO2019076904A1 (en) * 2017-10-16 2019-04-25 Esteve Pharmaceuticals, S.A. PROPANAMINE DERIVATIVES FOR THE TREATMENT OF PAIN AND PAIN DISEASES ASSOCIATED WITH PAIN
CN113121394B (zh) * 2019-12-30 2022-11-08 中国药科大学 一种苯氧乙酸类衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4313896A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Aryloxyphenylpropylamines
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
CA1337128C (en) * 1988-04-08 1995-09-26 David Wayne Robertson Propanamine derivatives

Also Published As

Publication number Publication date
NO178109B (no) 1995-10-16
EP0534756A2 (en) 1993-03-31
HUT65375A (en) 1994-05-02
CA2079161A1 (en) 1993-03-28
EP0534756A3 (en) 1993-06-16
CN1071416A (zh) 1993-04-28
YU87192A (sh) 1995-10-24
HU9203051D0 (en) 1992-12-28
JP3256291B2 (ja) 2002-02-12
TW249225B (enExample) 1995-06-11
NO923710D0 (no) 1992-09-24
ZA927240B (en) 1994-03-22
IL103277A (en) 1997-11-20
US5281624A (en) 1994-01-25
KR930005972A (ko) 1993-04-20
NZ244460A (en) 1994-10-26
MY108304A (en) 1996-09-30
IL103277A0 (en) 1993-02-21
BR9203743A (pt) 1993-04-20
JPH05201961A (ja) 1993-08-10
FI924305A0 (fi) 1992-09-25
FI111250B (fi) 2003-06-30
AU2537092A (en) 1993-04-01
NO923710L (no) 1993-03-29
KR100221180B1 (ko) 1999-09-15
ATE124934T1 (de) 1995-07-15
FI924305L (fi) 1993-03-28
HU215519B (hu) 1999-01-28
AU655075B2 (en) 1994-12-01
SK280480B6 (sk) 2000-02-14
NO178109C (no) 1996-01-24
JPH05238996A (ja) 1993-09-17
MX9205433A (es) 1993-03-01
CA2079161C (en) 2004-02-17
RU2057120C1 (ru) 1996-03-27
CA2079162A1 (en) 1993-03-28
SK290892A3 (en) 2000-02-14
CZ290892A3 (en) 1993-04-14
BR1100384A (pt) 1999-08-31
CN1033580C (zh) 1996-12-18
CZ281817B6 (cs) 1997-02-12
DE69203424D1 (de) 1995-08-17

Similar Documents

Publication Publication Date Title
DE69203424T2 (de) N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)Propylamine als Norepinephrineinhibitoren.
DE2500110C2 (enExample)
DE68922277T2 (de) Fluoxetin-Analogon.
DE2047658C3 (de) 2-Styryl- und 2-Phenyläthinylbenzylaminderivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE68916234T2 (de) Pharmazeutische zubereitungen für neuroschutz, die arylcyclohexylamine enthalten.
DE68917357T2 (de) Derivate der Coffeinsäure und pharmazeutische Zusammensetzungen, die sie enthalten.
DE69408078T2 (de) Phenylalkanolamin Derivate mit NMDA Rezeptor antagonistischer Wirkung
DE69520430T2 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
CH626343A5 (enExample)
DE3334757A1 (de) Piperazinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate
DE69628200T2 (de) Diarylalkenylamin-derivate
DE68901994T2 (de) Propanaminderivate.
DE3011504C2 (de) Farnesylessigsäureamide und diese enthaltende antibakterielle- und Antiulkusmittel
DE2556457C3 (de) N-(Pyrrolidin-2-yl-methyl)-2-methoxybenzamide, deren Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE60013818T2 (de) Quaternäre ammoniumverbindungen, verfahren zu deren herstellung und deren pharmazeutische verwendung
DE3879402T2 (de) Selektive sertonin-aufnahme-inhibitoren.
EP0537915B1 (en) N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
DE2614138C2 (de) Benzo[b]thienylcarbonylpropyl- bzw. Butylamine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE1695785C3 (de) 2-Aminomethyl-beitzofurane, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Präparate
EP0591581B1 (en) N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines
DE69619156T2 (de) Verwendung von alpha-Aminomethyl-3,4-dichlorbenzylthioaceamiden zur Herstellung eines dopaminwiederergreifungshemmenden Medikaments sowie Verbindungen zur Verwendung derselben
CH651021A5 (de) Quaternaere piperidinium-halogenide.
CH625207A5 (en) Process for the preparation of novel guanidine derivatives
JP3681770B2 (ja) 老年性痴呆症又はアルツハイマー病治療剤
AT352749B (de) Verfahren zur herstellung von neuen guanidin- derivaten und von deren saeureadditionssalzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee